share_log

Media Update: New Results From Rilzabrutinib Phase 2 Study Show Potential to Be First Advanced Oral Treatment for Moderate-to-severe Asthma

Media Update: New Results From Rilzabrutinib Phase 2 Study Show Potential to Be First Advanced Oral Treatment for Moderate-to-severe Asthma

媒體更新:Rilzabrutinib 2期研究的新結果顯示有可能成爲中度至重度哮喘的首款高級口服治療藥物
賽諾菲安萬特 ·  05/22 12:00

New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

rilzabrutinib 2期研究的新結果顯示,有可能成爲中度至重度哮喘的首款高級口服治療藥物

  • Late-breaking data presented at ATS show that treatment with rilzabrutinib led to a numerical reduction in loss of asthma control events, improvement in symptoms and was well-tolerated with no new safety signals observed
  • Results support the further development and advancement into a phase 3 program
  • Rilzabrutinib is one of 12 potential blockbusters in Sanofi's robust immunology pipeline and a testament to Sanofi's ability to successfully accelerate and build a portfolio of next-generation potentially transformative treatments for immune diseases
  • Rilzabrutinib is currently being studied in multiple indications, including recently reported positive results from a phase 3 study in ITP with regulatory submission in H2 2024 and positive results from a phase 2 study in CSU
  • 在ATS上公佈的最新數據顯示,使用rilzabrutinib進行治療可減少哮喘控制事件的數量,改善症狀,並且耐受性良好,未觀察到新的安全信號
  • 結果爲進一步發展和推進第三階段計劃提供了支持
  • Rilzabrutinib是賽諾菲強大的免疫學產品線中的12款潛在重磅產品之一,也證明了賽諾菲成功加速和建立下一代具有潛在變革性的免疫疾病治療產品組合的能力
  • Rilzabrutinib目前正在研究多種適應症,包括最近報告的ITP三期研究的陽性結果,該研究將於2024年下半年提交監管申請,以及科羅拉多州立大學一項2期研究的積極結果

Paris, May 22, 2024. Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma. These results were presented today as a late-breaking poster at the 2024 American Thoracic Society (ATS) International Conference in San Diego and will support the phase 3 program where a twice-daily dose of rilzabrutinib will be studied for moderate-to-severe asthma.

巴黎,2024年5月22日。一項令人鼓舞的2期研究結果表明,口服rilzabrutinib在高劑量和低劑量下均可導致哮喘失控(LOAC)事件(主要終點)的數值減少,且未受控制的中度至重度哮喘成年患者的症狀得到改善。這些結果今天作爲最新海報在聖地亞哥舉行的2024年美國胸科學會(ATS)國際會議上公佈,並將支持第三階段計劃,該計劃將研究每天兩次劑量的rilzabrutinib用於治療中度至重度哮喘。

Asthma is one of the most common chronic respiratory diseases affecting millions of people worldwide. Despite standard-of-care treatment, about 50% of patients with asthma remain uncontrolled with a high symptom burden that impacts their quality of life.

哮喘是影響全球數百萬人的最常見的慢性呼吸道疾病之一。儘管採用了標準的護理治療,但仍有大約 50% 的哮喘患者仍然無法控制,其症狀負擔過重,這會影響他們的生活質量。

Tanya M. Laidlaw, MD
Director of Translational Research in Allergy Brigham and Women's Hospital, Boston, MA
"Many of my patients with asthma who are treated with standard of care inhaled therapies, even those with infrequent asthma attacks, still suffer from asthma symptoms and their activities are limited because of it. These patients may not qualify for a biologic medicine today but could benefit from an oral therapy that intervenes earlier in the disease. These results are encouraging as they show an improvement in asthma symptoms and a numerical reduction in Loss of Asthma Control events – important parameters in the treatment of this chronic respiratory condition that can significantly impact our patients' daily lives."

Tanya M. Laidlaw,醫學博士
馬薩諸塞州波士頓布里格姆婦女醫院過敏轉化研究主任
“我的許多接受標準護理吸入療法治療的哮喘患者,即使是哮喘不經常發作的患者,仍然患有哮喘症狀,因此他們的活動受到限制。這些患者今天可能沒有資格使用生物藥物,但可以從疾病早期干預的口服療法中受益。這些結果令人鼓舞,因爲它們顯示哮喘症狀有所改善,哮喘控制失控事件數量有所減少,這些是治療這種慢性呼吸系統疾病的重要參數,可以顯著影響我們患者的日常生活。”

In this proof-of-concept study, treatment with high and low dose rilzabrutinib resulted in a 36% [OR: 0.584 (0.253, 1.349)] and 25% [OR:0.570 (0.202, 1.608)] relative risk reduction in loss of asthma control (LOAC) events, respectively, at week 12 (primary endpoint). Nominally significant and clinically meaningful improvements in asthma symptoms were also observed with a -0.54/-0.59 LS mean difference in asthma control questionnaire, ACQ-5. Improvements in ACQ-5 were seen as early as week 2.

在這項概念驗證研究中,在第12周(主要終點),使用高劑量和低劑量利扎布替尼治療使哮喘失控(LOAC)事件的相對風險分別降低了36% [OR:0.584(0.253,1.349)] 和25% [OR: 0.570(0.202,1.608)]。哮喘控制問卷(ACQ-5)的平均差異爲-0.54/-0.59 LS,也觀察到哮喘症狀的名義上顯著且具有臨床意義的改善。早在第 2 周,ACQ-5 就出現了改善。

Rilzabrutinib high and low doses were well tolerated over 12 weeks of treatment with no events of cytopenia, hemorrhagic events, or atrial fibrillation and no imbalance in liver function tests. Treatment-emergent adverse events (TEAEs) occurring with higher frequency with rilzabrutinib versus placebo were diarrhea (10.9% and 9.4% with rilzabrutinib high and low dose, versus 0% and 3.1% with matching placebo, respectively).

Rilzabrutinib的高劑量和低劑量在治療12周內均表現良好,沒有出現血細胞減少、出血事件或心房顫動,肝功能測試也沒有失衡。與安慰劑相比,利扎布替尼發生的治療緊急不良事件(TEAE)頻率更高,是腹瀉(高劑量和低劑量利扎布替尼分別爲10.9%和9.4%,而配套安慰劑分別爲0%和3.1%)。

Houman Ashrafian
Executive Vice President, Head of Research and Development, Sanofi
"We are incredibly encouraged by the reduction in loss of asthma control events and improvements in asthma symptoms and look forward to advancing rilzabrutinib into a broader phase 3 clinical development program to further explore its potential in this disease. Advanced oral therapies have the potential to change the treatment paradigm for diseases like asthma, and we remain committed to exploring disruptive mechanisms of action for people living with uncontrolled chronic inflammatory diseases."

霍曼·阿什拉菲安
賽諾菲執行副總裁兼研發主管
“哮喘控制事件的減少和哮喘症狀的改善使我們深受鼓舞,並期待將rilzabrutinib推進到更廣泛的3期臨床開發計劃,以進一步探索其在該疾病中的潛力。先進的口服療法有可能改變哮喘等疾病的治療模式,我們仍然致力於爲不受控制的慢性炎症性疾病患者探索顛覆性的作用機制。”

Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Rilzabrutinib目前正在臨床研究中,其安全性和有效性尚未經過任何監管機構的評估。

About the study
This phase 2 study is a randomized, double-blind, placebo-controlled, parallel-group, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of rilzabrutinib in participants with moderate-to-severe asthma who are not well controlled on inhaled corticosteroid (ICS) plus long-acting β2 adrenergic agonist (LABA) therapy. Two doses of rilzabrutinib, 800 mg daily and 1200 mg daily, were studied. Patients were randomized 1:1 to receive either rilzabrutinib or placebo to be added to a background therapy of ICS/LABA which was withdrawn during the 12-week treatment period.

關於這項研究
這項 2 期研究是一項隨機、雙盲、安慰劑對照、平行組、爲期 12 周的概念驗證研究,旨在評估 rilzabrutinib 對吸入性皮質類固醇 (ICS) 加長效 β2 腎上腺素激動劑 (LABA) 治療未得到良好控制的中度至重度哮喘參與者的療效、安全性和耐受性。研究了兩劑利扎布替尼,每日800毫克,每天1200毫克。患者以 1:1 的隨機分配,接受利扎布替尼或安慰劑,加入在12周治療期內停止的ICS/LABA背景療法中。

The primary endpoint was reduction in LOAC events. Secondary endpoints included asthma control (measured by the asthma control questionnaire, ACQ-5) and asthma quality of life (measured by the asthma quality of life questionnaire, AQLQ) or lung function (measured by FEV1).

主要終點是減少LOAC事件。次要終點包括哮喘控制(通過哮喘控制問卷測量,ACQ-5)和哮喘生活質量(通過哮喘生活質量問卷AQLQ測量)或肺功能(由FEV1測量)。

About rilzabrutinib
Rilzabrutinib is an oral, reversible, covalent BTK inhibitor that has the potential to be a first- and/or best-in-class treatment for several immune-mediated diseases. BTK, expressed in B cells and mast cells, plays a critical role in multiple immune-mediated disease processes. With the application of Sanofi's TAILORED COVALENCY technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side effects.

關於利扎布替尼
Rilzabrutinib是一種口服、可逆的共價BTK抑制劑,有可能成爲幾種免疫介導疾病的首創和/或同類最佳治療方法。BTK 在 B 細胞和肥大細胞中表達,在多種免疫介導的疾病過程中起着至關重要的作用。通過應用賽諾菲的 TAILOREND COVALENCY 技術,rilzabrutinib可以選擇性地抑制BTK靶點,同時有可能降低脫靶副作用的風險。

Rilzabrutinib is being studied across a variety of immune-mediated diseases, including immune thrombocytopenia (ITP), asthma, chronic spontaneous urticaria, prurigo nodularis, IgG4-related disease, and warm autoimmune hemolytic anemia.

Rilzabrutinib正在研究各種免疫介導疾病,包括免疫血小板減少症(ITP)、哮喘、慢性自發性蕁麻疹、結節性瘙癢、IgG4相關疾病和溫熱性自身免疫性溶血性貧血。

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

關於賽諾菲
我們是一家創新的全球醫療保健公司,我們的目標只有一個:我們追逐科學奇蹟以改善人們的生活。我們的團隊遍佈世界各地,致力於將不可能變爲可能,從而改變醫學實踐。我們爲全球數百萬人提供可能改變生活的治療選擇和挽救生命的疫苗保護,同時將可持續發展和社會責任置於我們雄心壯志的中心。
賽諾菲在泛歐交易所:SAN 和納斯達克上市:SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com

媒體關係
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
埃文·伯蘭德 | +1 215 432 0234 | evan.berland@sanofi.com
尼古拉斯·奧布里斯特 | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
蒂莫西·吉爾伯特 | + 1 516 521 2929 | timothy.gilbert@sanofi.com

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

投資者關係
托馬斯·庫德斯克·拉森 |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizeé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

賽諾菲前瞻性陳述
本新聞稿包含經修訂的1995年《私人證券訴訟改革法》中定義的前瞻性陳述。前瞻性陳述是不是歷史事實的陳述。這些陳述包括預測和估計及其基本假設,有關計劃、目標、意圖和對未來財務業績、事件、運營、服務、產品開發和潛力的預期的陳述,以及有關未來業績的陳述。前瞻性陳述通常由 “期望”、“預期”、“相信”、“打算”、“估計”、“計劃” 和類似表述來識別。儘管賽諾菲管理層認爲此類前瞻性陳述中反映的預期是合理的,但提醒投資者,前瞻性信息和陳述存在各種風險和不確定性,其中許多風險和不確定性難以預測,通常超出賽諾菲的控制範圍,這可能導致實際業績和發展與前瞻性信息和陳述所表達、暗示或預測的業績和發展存在重大差異。除其他外,這些風險和不確定性包括研發固有的不確定性、未來的臨床數據和分析,包括上市後的分析、監管機構(例如FDA或EMA)關於是否及何時批准任何此類候選產品可能申請的任何藥物、設備或生物學應用的決定,以及他們關於標籤和其他可能影響此類候選產品可用性或商業潛力的事項的決定,候選產品如果獲得批准的事實可能不會在商業上取得成功、替代療法的未來批准和商業成功、賽諾菲從外部增長機會中受益、完成關聯交易和/或獲得監管許可的能力、與知識產權和任何相關的未決或未來訴訟相關的風險以及此類訴訟的最終結果、匯率和現行利率的趨勢、動盪的經濟和市場狀況、成本控制舉措及其後續變化,以及疫情的影響其他全球危機可能對我們、我們的客戶、供應商、供應商和其他商業夥伴以及其中任何一個的財務狀況以及我們的員工和整個全球經濟造成影響。風險和不確定性還包括賽諾菲在向美國證券交易委員會和AMF提交的公開文件中討論或確定的不確定性,包括賽諾菲截至2023年12月31日止年度的20-F表年度報告中 “風險因素” 和 “關於前瞻性陳述的警示性聲明” 中列出的不確定性。除適用法律的要求外,賽諾菲不承擔任何更新或修改任何前瞻性信息或陳述的義務。

Attachment

附件

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論